Research compounds
N-Acetyl Selank Amidate
NA-Selank-Amidate
N-Acetyl Selank Amidate is a modified form of Selank, a synthetic analogue of the immunomodulatory peptide tuftsin developed in Russia and registered there as an anxiolytic. The modified form is sold as a research peptide and is not approved by the FDA or EMA.
Also known as: N-Acetyl Selank, Selank amidate
- Status
- N-Acetyl Selank Amidate is a research compound and not approved by the FDA for human use.
- Evidence
- Anecdotal. Mostly community reports; there is no controlled human data.
- Half-life
- Not established for the modified form; unmodified Selank is cleared very rapidly.
- How it's taken
- Intranasal in non-clinical use
- Mechanism
- Cognitive / mood
- Pathways
- Neurotrophic
How N-Acetyl Selank Amidate works
Selank is a heptapeptide combining the tuftsin sequence with a stabilising tripeptide. Its anxiolytic effect is attributed to modulation of GABAergic and serotonergic signalling and to effects on the expression of enkephalin-degrading enzymes, raising endogenous enkephalin tone. Unlike benzodiazepines it does not act as a direct GABA-A positive allosteric modulator, which is the basis for claims that it lacks sedation and dependence. Acetylation and amidation are intended to slow degradation.
What research has looked at
- Selank is registered in Russia for generalised anxiety disorder, and Russian trials report anxiolytic effects without the sedation and dependence associated with benzodiazepines.
- Its mechanism differs from benzodiazepines, which is the mechanistic basis for the absence of a withdrawal syndrome in the reported data.
- Intranasal delivery avoids injection, and the parent compound has been in clinical use in Russia for years with a benign reported side-effect profile.
Evidence level: Anecdotal. Mostly community reports; there is no controlled human data. These are areas studied or reported, not promised effects.
Reported side effects and risks
- As with Semax, the evidence base is predominantly Russian-language and has not been replicated to Western regulatory standards. The modified variant specifically has essentially no published human data.
- It is not approved by the FDA or EMA for any indication.
- Material sold as NA-Selank-Amidate is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- Anxiety is a condition with a large placebo response and subjective endpoints, which makes uncontrolled user reports particularly unreliable as evidence.
- Long-term safety is unstudied.
Sources
- PubMed research on N-acetyl Selank amidate anxiolytic tuftsin · NIH · National Library of Medicine
- DrugBank record for Selank · DrugBank
- Active clinical trials for Selank · U.S. National Library of Medicine
Track N-Acetyl Selank Amidate in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
N-Acetyl Selank Amidate FAQ
What is N-Acetyl Selank Amidate?
N-Acetyl Selank Amidate is a modified form of Selank, a synthetic analogue of the immunomodulatory peptide tuftsin developed in Russia and registered there as an anxiolytic. The modified form is sold as a research peptide and is not approved by the FDA or EMA.
How does N-Acetyl Selank Amidate work?
Selank is a heptapeptide combining the tuftsin sequence with a stabilising tripeptide. Its anxiolytic effect is attributed to modulation of GABAergic and serotonergic signalling and to effects on the expression of enkephalin-degrading enzymes, raising endogenous enkephalin tone. Unlike benzodiazepines it does not act as a direct GABA-A positive allosteric modulator, which is the basis for claims that it lacks sedation and dependence. Acetylation and amidation are intended to slow degradation.
Is N-Acetyl Selank Amidate FDA approved?
No. N-Acetyl Selank Amidate is a research compound and not approved by the FDA for human use. Evidence level: anecdotal. Mostly community reports; there is no controlled human data.
How is N-Acetyl Selank Amidate taken?
Intranasal in non-clinical use.
What side effects have been reported with N-Acetyl Selank Amidate?
Reported in the sources: As with Semax, the evidence base is predominantly Russian-language and has not been replicated to Western regulatory standards. The modified variant specifically has essentially no published human data; It is not approved by the FDA or EMA for any indication; Material sold as NA-Selank-Amidate is research chemical supply with unverified identity, purity, sterility and dose accuracy; Anxiety is a condition with a large placebo response and subjective endpoints, which makes uncontrolled user reports particularly unreliable as evidence; Long-term safety is unstudied.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.